FDA compliance, medical and affiliate disclosures for Vinetaro and this website.
These statements have not been evaluated by the U.S. Food & Drug Administration. Vinetaro is a dietary supplement, not a drug, and is not intended to diagnose, treat, cure or prevent any disease, including type 1 or type 2 diabetes or any other diagnosed medical condition. It is designed to support healthy blood sugar levels already within normal range, energy and overall metabolic wellness as part of a balanced diet and active lifestyle. Individual results vary. Several Vinetaro ingredients (including Gymnema Sylvestre, Banaba Leaves, Bitter Melon, Cinnamon Bark and Chromium) can affect blood sugar levels and may interact with insulin, metformin, sulfonylureas and other diabetes medications, increasing the risk of hypoglycemia. This product is intended for healthy adults 18 years of age or older. If you have diabetes, take blood-sugar-lowering medication, are pregnant, nursing, or have a medical condition, consult your doctor before use.
The content on Vinetarro.com, including blog articles, reviews and FAQs, is provided for general informational purposes only and does not constitute medical advice. Always consult a licensed healthcare professional before starting Vinetaro or any new dietary supplement, particularly if you have diabetes or take blood-sugar-lowering medication.
Several Vinetaro ingredients — including Gymnema Sylvestre, Banaba Leaves, Bitter Melon, Cinnamon Bark and Chromium — can affect blood sugar levels and may interact with insulin, metformin, sulfonylureas and other diabetes medications, increasing the risk of hypoglycemia. Consult your doctor before use if this applies to you.
Testimonials and reviews on this site reflect individual experiences and are not guarantees of results. Factors such as diet, activity level, age and overall health can all affect outcomes.
This website may earn a commission on purchases made through links to the official Vinetaro store, at no additional cost to you. This does not influence our editorial assessments — see our editorial standards.